Form 4: Apogee Therapeutics Director Nimish Shah Acquires Stock Options

Director Nimish Shah of Apogee Therapeutics acquired stock options for 10,370 shares of common stock on June 5, 2024, according to a recent SEC filing.

Summary

• Nimish Shah, a director of Apogee Therapeutics, acquired stock options to purchase 10,370 shares of the company's common stock on June 5, 2024.
• The exercise price of these options is $43.85 per share.
• The options vest one year from the grant date, contingent upon Shah's continued service to Apogee Therapeutics.
• Shah is deemed to hold the options and underlying shares for the benefit of VR Management, LLC, and must exercise the options at their direction.
• A Power of Attorney was executed on June 3, 2024, granting certain individuals the authority to file Forms 3, 4, and 5 on Shah's behalf.

Sentiment

Score: 5

Explanation: This is a neutral event, reflecting a standard stock option grant to a company director. It doesn't inherently indicate positive or negative sentiment.

Future Outlook

The options will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and equity ownership of company directors.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects a standard compensation practice.
• Employees may view the option grant as a positive sign of management's commitment.

Key Dates